Filing Analysis
Rezolute, Inc. held its 2026 annual meeting of stockholders on November 19, 2025. The filing reports the final voting results for director elections, auditor ratification, say-on-pay, and an equity plan amendment.
🚩 Red Flags
- Significant 'Against' vote on Say-on-Pay proposal (approximately 32% of votes cast were against executive compensation).
📋 Key Facts
- Annual meeting held virtually on November 19, 2025.
- Quorum was present with 66,700,068 shares represented (out of 90,811,368 outstanding).
- All seven director nominees were elected to the board.
- Grant Thornton LLP was ratified as independent auditor for fiscal year ending June 30, 2026.
- The 'Say-on-Pay' advisory vote on executive compensation received significant opposition (19.1M against vs 40.1M for).
- Shareholders approved an amendment to the 2021 Stock Incentive Plan to increase available shares from 14,450,000 to 21,950,000.
Rezolute, Inc. held an investor event and presentation on November 10, 2025, to provide a clinical development update regarding its Ersodetug program.
📋 Key Facts
- The company hosted an investor event and related presentation on November 10, 2025.
- The primary focus of the presentation was an update on the Ersodetug development program.
- The filing includes Exhibit 99.1 containing the presentation materials.
Rezolute, Inc. filed an 8-K to announce its financial results for the first quarter ended September 30, 2025.
📋 Key Facts
- The filing is a standard announcement of quarterly financial results (Item 2.02).
- Reporting period: First quarter ended September 30, 2025.
- Filing date: November 6, 2025.
Rezolute, Inc. has amended employment agreements for its top four executives to include tax gross-up provisions in the event of a change of control. Additionally, the company is terminating its at-the-market (ATM) equity offering agreement with Jefferies LLC.
🚩 Red Flags
- Executive compensation amendments involving tax gross-ups for change of control events can be viewed as a misalignment of interests or 'golden parachutes'.
- Termination of an ATM agreement, while not inherently negative if unused, indicates a cessation of a primary capital raising mechanism.
📋 Key Facts
- On October 17, 2025, CEO Nevan C. Elam, CMO Brian Roberts, CFO Daron Evans, and CCO Sunil Karnawat entered into employment agreement amendments.
- Amendments include a full gross-up payment for excise taxes/local/state/federal taxes resulting from Section 280G 'parachute payments' during a change of control event.
- The company is terminating its Open Market Sale Agreement with Jefferies LLC, effective October 24, 2025.
- The ATM program under the S-3 registration statement had not been utilized by the company prior to termination.
Rezolute, Inc. filed an 8-K to announce its financial results for the fourth quarter and fiscal year ended June 30, 2025. The filing serves as a formal announcement of the release of these earnings results.
📋 Key Facts
- Report date: September 17, 2025
- Reporting period: Fourth quarter and fiscal year ended June 30, 2025
- The filing includes a press release (Exhibit 99.1) containing the financial results.
Rezolute, Inc. issued a press release regarding FDA alignment on the design of its ongoing Phase 3 trial for Ersodetug in Tumor Hyperinsulinism and updated its corporate presentation.
📋 Key Facts
- Company reached alignment with the FDA on the design of the Phase 3 trial for Ersodetug (upLIFT study).
- The filing includes an updated corporate presentation reflecting recent developments.
Rezolute, Inc. announced the appointment of Dr. Sunil Karnawat as Chief Commercial Officer on August 18, 2025. The appointment includes a comprehensive compensation package consisting of salary, bonuses, and equity incentives.
📋 Key Facts
- Dr. Sunil Karnawat appointed as Chief Commercial Officer effective August 18, 2025.
- Annual base salary set at $475,000 with a $65,000 signing bonus.
- Target annual incentive compensation is up to 40% of base salary.
- Equity compensation includes 270,000 stock options and 25,000 restricted stock units (RSUs).
- Dr. Karnawat previously held leadership roles at Cytokinetics Pharmaceuticals and Ultragenyx Pharmaceuticals.
Rezolute, Inc. filed an 8-K to disclose a patient demographic poster related to its Phase 3 clinical study (sunRIZE). The filing is primarily for regulatory compliance regarding Regulation FD disclosure.
📋 Key Facts
- The company posted a patient demographic poster for its sunRIZE Phase 3 clinical study on July 15, 2025.
- The information was released via the company's website and included as Exhibit 99.1.
- The disclosure is intended to satisfy Regulation FD requirements.
Rezolute, Inc. filed an 8-K/A to supplement a previous filing regarding the appointment of Erik Harris to its Board of Directors. The amendment specifies his assignment to the Compensation Committee effective July 1, 2025.
📋 Key Facts
- Erik Harris was originally appointed to the Board on March 25, 2025.
- The Board has now officially appointed Mr. Harris to the Compensation Committee.
- The committee appointment is effective as of July 1, 2025.
- This is an amendment (8-K/A) to a previous filing dated March 28, 2025.
Rezolute, Inc. completed a private placement of common stock on June 13, 2025. The company issued 1,295,383 shares to investors for an aggregate purchase price of approximately $4.21 million.
🚩 Red Flags
- Unregistered securities: The shares are being issued without registration, which may lead to future dilution or liquidity constraints for retail investors.
- Reliance on private placements: Indicates a need for immediate capital infusion, common in micro-cap biotech/development stage companies.
📋 Key Facts
- Date of transaction: June 13, 2025
- Total shares issued: 1,295,383 Private Placement Shares
- Aggregate purchase price: $4,209,994.75
- The offering was conducted via a Securities Purchase Agreement with certain investors.
- Shares were issued under an exemption from registration in reliance upon Section 4(a)(2) of the Securities Act.
Rezolute, Inc. filed an 8-K to announce its financial results for the third quarter ended March 31, 2025. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Report date: May 13, 2025
- Reporting period: Third quarter ended March 31, 2025
- The filing includes a press release as Exhibit 99.1 regarding financial results.
Rezolute, Inc. announced the closing of an underwritten securities offering on April 25, 2025. The filing serves to provide notice via a press release incorporated by reference.
🚩 Red Flags
- Dilution risk typically associated with underwritten offerings in micro-cap biotech companies.
📋 Key Facts
- The company closed an underwritten offering on April 25, 2025.
- The announcement was made via a press release included as Exhibit 99.1.
- Reporting date of the event is April 25, 2025; filing date is April 28, 2025.
Rezolute, Inc. announced a significant registered direct offering of common stock and pre-funded warrants totaling approximately $84.2 million, alongside a separate $10 million private placement to insiders.
🚩 Red Flags
- Significant dilution: The issuance of over 20 million shares plus warrants represents a substantial increase in share count.
- Insider Private Placement: A $10M transaction with insiders at the same price as the public offering is noted as exceeding market value for Nasdaq Rule 5635(c) purposes.
📋 Key Facts
- Registered Direct Offering: 20,786,923 shares at $3.25 per share.
- Pre-Funded Warrants: Up to 6,905,385 warrants at $3.249 per warrant (exercise price of $0.001).
- Underwriter Option: Guggenheim Securities has an option for up to 4,153,846 additional shares.
- Estimated Net Proceeds: Approximately $84.2 million (up to $96.9 million if option is exercised).
- Private Placement: Insiders agreed to purchase up to $10,000,000 of common stock at $3.25 per share.
- Use of Proceeds: Research and development, working capital, and general corporate purposes.
- Lock-up Period: 90 days for executive officers, directors, and certain stockholders.
Rezolute, Inc. issued a press release announcing positive results from an independent interim analysis of its Phase 3 sunRize study. The filing serves as a Regulation FD disclosure to communicate clinical trial progress.
📋 Key Facts
- Date of report: April 23, 2025
- The company received a positive recommendation following an independent interim analysis of the Phase 3 sunRize study.
- The announcement was made via press release (Exhibit 99.1) to comply with Regulation FD.
Rezolute, Inc. announced the election of Erik Harris to its Board of Directors, effective March 25, 2025. Mr. Harris is an experienced biopharmaceutical commercial executive who currently serves on multiple public boards.
📋 Key Facts
- Erik Harris elected to the Board of Directors effective March 25, 2025.
- Mr. Harris was determined by the Board to be 'independent' per Nasdaq listing requirements.
- Compensation includes an annual cash retainer and a grant of 60,000 stock options with an exercise price of $2.89.
- Options vest monthly in equal installments starting March 25, 2025, and expire in 2035.
- Mr. Harris has extensive commercial leadership experience at Ultragenyx Pharmaceutical, Crescendo Bioscience, InterMune, Elan Pharmaceuticals, Genentech, and Bristol-Myers Squibb.
Rezolute, Inc. filed an 8-K to announce its financial results for the second quarter ended December 31, 2024.
📋 Key Facts
- Reporting period: Second quarter ended December 31, 2024.
- Filing date: February 12, 2025.
- The filing includes a press release (Exhibit 99.1) detailing financial results.
Rezolute, Inc. issued a press release regarding the outcomes of an independent Data Monitoring Committee (DMC) review for its sunRIZE Phase 3 study of ersodetug. The filing also provides updates on upcoming interim analysis guidance by the DMC.
📋 Key Facts
- The announcement concerns the open-label arm portion of the sunRIZE Phase 3 study of ersodetug.
- The study targets the treatment of hypoglycemia due to congenital hyperinsulinism.
- An independent Data Monitoring Committee (DMC) has reviewed the open-label arm data.
- The company provided guidance regarding an upcoming interim analysis by the DMC.
Rezolute, Inc. filed an 8-K to disclose a pre-recorded video and transcript detailing a patient's participation in the company's Phase 2 clinical study via Regulation FD disclosure.
📋 Key Facts
- The filing relates to a webcast/video released on January 10, 2025.
- The content focuses on testimonial data from a patient participating in a Phase 2 clinical study.
- The transcript of the video is included as Exhibit 99.1.
Rezolute, Inc. announced that the FDA has granted Breakthrough Therapy Designation to its drug candidate ersodetug (RZ358) for treating hypoglycemia caused by congenital hyperinsulinism.
📋 Key Facts
- FDA granted Breakthrough Therapy Designation for ersodetug (formerly RZ358).
- Target indication: Hypoglycemia due to congenital hyperinsulinism.
- Filing date: January 7, 2025.
Rezolute, Inc. reported the results of its 2025 annual meeting of stockholders held on December 5, 2024. Shareholders approved several key measures, including the election of directors and a significant increase in authorized common stock.
🚩 Red Flags
- Significant increase in authorized share count (from 100M to 165M) can lead to future dilution for existing shareholders.
📋 Key Facts
- Shareholders approved an amendment to increase authorized common stock from 100,000,000 to 165,000,000 shares (Proposal No. 4).
- The 2021 Stock Incentive Plan was amended to increase available shares from 10,700,000 to 14,450,000 (Proposal No. 5).
- Grant Thornton LLP was ratified as the independent registered public accounting firm for the fiscal year ending June 30, 2025.
- Six directors were elected to the Board of Directors: Nevan Charles Elam, Young-Jin Kim, Gil Labrucherie, Philippe Fauchet, Nerissa Kreher, and Wladimir Hogenhuis.
- A quorum was present at the meeting with 36,588,042 shares represented out of 55,927,913 outstanding.
Rezolute, Inc. filed an 8-K to announce its financial results for the first quarter ended September 30, 2024.
📋 Key Facts
- Report date: November 7, 2024
- Reporting period: First quarter ended September 30, 2024
- The filing serves to announce the release of quarterly financial results via press release (Exhibit 99.1).
Rezolute, Inc. filed an 8-K to announce its financial results for the fourth quarter and fiscal year ended June 30, 2024. The filing serves as a formal announcement of the earnings release issued on September 19, 2024.
📋 Key Facts
- Reporting period: Fourth quarter and fiscal year ended June 30, 2024.
- Announcement date: September 19, 2024.
- The filing includes a press release as Exhibit 99.1 containing the financial results.
Rezolute, Inc. announced that the FDA has completely removed all partial clinical holds on its drug candidate RZ358 (ersodetug) for treating hypoglycemia in patients with congenital hyperinsulinism.
📋 Key Facts
- FDA has completely removed the partial clinical holds on RZ358 (ersodetug).
- The target indication is hypoglycemia resulting from congenital hyperinsulinism.
- Announcement date: September 9, 2024.
Rezolute, Inc. announced FDA clearance of its Investigational New Drug (IND) application for RZ358 (ersodetug) to treat hypoglycemia in patients with tumor hyperinsulinism. The company also released an updated corporate presentation.
📋 Key Facts
- FDA cleared the IND application for RZ358 (ersodetug).
- Target indication: Hypoglycemia in patients with tumor hyperinsulinism.
- Company issued an updated Corporate Presentation on August 5, 2024.
Rezolute, Inc. has released an updated data presentation regarding its RZ402 program, including an added Appendix to the presentation originally shared in May 2024.
📋 Key Facts
- The company made available the RZ402 data presentation and a new Appendix on its website on June 28, 2024.
- The original presentation was first released during an investor/media webcast on May 21, 2024.
- The filing includes Exhibit 99.1 containing the updated RZ402 data presentation.
Rezolute, Inc. entered into a securities purchase agreement for a private placement of 1,500,000 shares of common stock at $4.00 per share. The transaction is expected to raise approximately $6.0 million in gross proceeds to fund clinical R&D and working capital.
🚩 Red Flags
- Registration Rights Agreement includes liquidated damages if the company fails to maintain effectiveness or meet filing deadlines.
- Potential for future dilution due to the requirement to register the private shares for resale.
📋 Key Facts
- Private placement of 1,500,000 shares of Common Stock.
- Share price set at $4.00 per share (representing a premium to the June 25, 2024 closing bid).
- Expected gross proceeds: approximately $6.0 million.
- Use of proceeds: clinical research and development, working capital, and general corporate purposes.
- Includes a Registration Rights Agreement requiring the company to file a resale registration statement within 30 days of payment.
Rezolute, Inc. entered into an underwriting agreement on June 13, 2024, to conduct a public offering of common stock and pre-funded warrants. The offering aims to raise approximately $56 million in net proceeds to fund R&D and working capital.
🚩 Red Flags
- Significant dilution potential due to the issuance of 11.25M shares plus up to 3.75M warrants.
- Pre-funded warrants allow investors to bypass certain ownership thresholds (4.99%/19.99%) while effectively holding equity, which can impact voting power and cap table structure.
📋 Key Facts
- Underwriting Agreement signed with Jefferies LLC and Cantor Fitzgerald & Co. on June 13, 2024.
- Offering includes 11,250,000 shares of common stock at $4.00 per share.
- Offering includes up to 3,750,000 pre-funded warrants at $3.999 per warrant (exercise price of $0.001).
- Underwriters have a 30-day option to purchase an additional 2,250,000 shares at $4.00 per share.
- Estimated net proceeds: ~$56 million (up to ~$64.5 million if all options are exercised).
- Use of proceeds: Research and development, working capital, and general corporate purposes.
Rezolute, Inc. announced positive topline results from a Phase 2 clinical study of its drug candidate RZ402 for the treatment of diabetic macular edema.
📋 Key Facts
- Announced positive topline results from a Phase 2 clinic study of RZ402.
- Study involved 94 patients with diabetic macular edema.
- Patient population included those naïve to or who had received limited anti-vascular growth factor injections.
- The announcement was made via press release on May 21, 2024.
Rezolute, Inc. held its 2024 annual meeting of stockholders on May 16, 2024, reporting the results of shareholder votes regarding director elections and other proposals.
📋 Key Facts
- Annual meeting held virtually on May 16, 2024.
- Quorum was present with 27,494,377 shares represented out of 40,127,647 outstanding shares.
- All six nominees for the Board of Directors were elected: Young-Jin Kim, Nevan Charles Elam, Philippe Fauchet, Gil Labrucherie, Wladimir Hogenhuis, and Nerissa Kreher.
- Shareholders ratified Grant Thornton LLP as the independent registered public accounting firm for fiscal year 2024.
- The 'Say-on-Pay' advisory vote on executive compensation was approved.
- An amendment to the 2021 Stock Incentive Plan regarding incentive compensation recovery policy was approved.
Rezolute, Inc. filed an 8-K to announce its financial results for the third quarter ended March 31, 2024.
📋 Key Facts
- Report date: May 15, 2024
- Reporting period: Third quarter ended March 31, 2024
- The filing includes a press release (Exhibit 99.1) detailing financial results.
Rezolute, Inc. announced that Dr. Paul Thornton will present Phase 2 RIZE study results at the upcoming Pediatric Endocrine Society Annual Meeting in May 2024.
📋 Key Facts
- Event: Presentation of Phase 2 RIZE study results.
- Presenter: Paul Thornton, M.D.
- Conference: Pediatric Endocrine Society Annual Meeting.
- Date of Conference: May 2-5, 2024.
- Location: Sheraton Grand Chicago Riverwalk.
Rezolute, Inc. announced the dismissal of its independent auditor, Plante & Moran, PLLC, and the appointment of Grant Thornton LLP as its new accounting firm. Simultaneously, the company entered into a securities exchange agreement to retire 3,000,000 shares in exchange for pre-funded warrants.
🚩 Red Flags
- Auditor change (dismissal of Plante Moran) occurring alongside a significant equity restructuring/share retirement.
- Previous disclosure of material weakness in internal controls over financial reporting (as noted in 2022 10-K).
📋 Key Facts
- Dismissed Plante & Moran, PLLC as independent registered public accounting firm on March 8, 2024.
- Appointed Grant Thornton LLP as the new independent registered public accounting firm.
- Entered into a securities exchange agreement to retire 3,000,000 shares of common stock.
- Retired shares were exchanged for pre-funded warrants to purchase 3,000,000 shares at an exercise price of $0.001 per share.
- The company will file a registration statement within six months to cover the resale of shares issuable upon warrant exercise.
Rezolute, Inc. issued a press release regarding positive preclinical pharmacology study results for RZ358 as a potential treatment for hypoglycemia.
📋 Key Facts
- Report date: March 6, 2024; Filing date: March 11, 2024
- Announced results from a preclinical pharmacology study on RZ358
- Target indication: Hypoglycemia treatment
- The disclosure was made under Item 7.01 (Regulation FD Disclosure)
Rezolute, Inc. has successfully regained compliance with Nasdaq's $1.00 minimum bid price requirement. This follows a period of non-compliance triggered by the stock trading below $1.00 for 30 consecutive days.
🚩 Red Flags
- Historical stock price volatility that led to a delisting warning (trading below $1.00 for 30 consecutive days).
📋 Key Facts
- Company received notice on November 21, 2023, regarding non-compliance with Nasdaq Listing Rule 5550(a)(2).
- The company was required to maintain a closing bid price of $1.00 or more for at least 10 consecutive business days.
- Compliance requirement was officially met on February 20, 2024.
- Nasdaq notified the company of regained compliance on February 21, 2024.
Rezolute, Inc. filed an 8-K to announce its financial results for the second quarter ended December 31, 2023. The filing serves as a formal announcement of the earnings release issued on February 13, 2024.
📋 Key Facts
- Report date: February 13, 2024
- Reporting period: Second quarter ended December 31, 2023
- The filing includes a press release as Exhibit 99.1 regarding financial results.
Rezolute, Inc. announced the appointment of Daron Evans as Chief Financial Officer on January 23, 2024. The appointment includes an inducement grant of stock options to align executive interests with shareholders.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Daron Evans appointed as CFO effective January 23, 2024.
- Compensation package includes a $275,000 annual base salary and a target annual performance bonus of 50% of base salary.
- Inducement Grant: 275,000 stock options at an exercise price of $1.02 per share.
- Vesting schedule for options: 25% on the first anniversary; remaining 75% in 36 equal monthly installments thereafter.
- Acceleration clause: All remaining options vest automatically upon company acquisition during his employment.
- Regulatory milestone: UK MHRA awarded 'Innovation Passport' to RZ358 for treating hypoglycemia due to congenital hyperinsulinism.